WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus

Ersoy, Gülçı̇n Şahin; Ensarı, Tuğba Altun; Subaş, Seda; Giray, Burak; Şimşek, Engin Ersin; Çevik, Özge

doi:10.1080/14767058.2016.1192118

Cited by 39 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, our findings demonstrated that prepregnancy overweight/obesity interacted with GDM to affect circulatory concentration of WISP1 (Figure 1(b)). Similarly, it has been reported that circulating WISP1 in the GDM group is significantly higher than that in the control group [15].…”

Section: Disease Markersmentioning

confidence: 54%

“…WISP1 is involved in a wide range of biological functions and pathological processes, such as cell growth, differentiation, and survival [13,14]. And overexpressed WISP1 has been observed in several diseases including GDM [15], hypertension [16], obesity [17,18], lung fibroblasts [19], and several types of cancer [20]. WISP1 is widely expressed in normal tissues, particularly in human adipose tissue.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women

Liu

Yang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. Obese women with gestational diabetes mellitus (GDM) have a higher risk of adverse outcomes than women with obesity or GDM alone. Our study is aimed at investigating the discriminatory power of circulatory Wnt1-inducible signaling pathway protein-1 (WISP1), a novel adipocytokine, on the copresence of prepregnancy overweight/obesity and GDM and at clarifying the relationship between the WISP1 level and clinical cardiometabolic parameters. Methods. A total of 313 participants were screened from a multicenter prospective prebirth cohort: Born in Shenyang Cohort Study (BISCS). Subjects were examined with a 2×2 factorial design for body mass index BMI≥24 and GDM. Between 24 and 28 weeks of pregnancy, follow-up individuals underwent an OGTT and blood sampling for cardiometabolic characterization. Results. We observed that the WISP1 levels were elevated in prepregnancy overweight/obesity patients with GDM, compared with nonoverweight subjects with normal blood glucose (3.45±0.89 vs. 2.91±0.75 ng/mL). Multilogistic regression analyses after adjustments for potential confounding factors revealed that WISP1 was a strong and independent risk factor for prepregnancy overweight/obesity with GDM (all ORs>1). In addition, the results of the ROC analysis indicated that WISP1 exhibited the capability to identify individuals with prepregnancy overweight/obesity and GDM (all AUC>0.5). Finally, univariate and multivariate linear regression showed that WISP1 level was positively and independently correlated with fasting blood glucose, systolic blood pressure, and aspartate aminotransferase and was negatively correlated with HDL-C and complement C1q. Conclusions. WISP1 may be critical for the prediction, diagnosis, and therapeutic strategies against obesity and GDM in pregnant women.

show abstract

Section: Disease Markersmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women

Liu

Yang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Disorders such as DM affect all systems of the body (10, 11, 53–60). For example, DM can negatively impact the immune system, musculoskeletal function, hepatic metabolism, and renal clearance (50, 53, 55, 59, 61–64).…”

Section: Increased Lifespan Degenerative Disorders and Cell Injurymentioning

confidence: 99%

“…EPO also fosters microglial survival during oxidative stress through mTOR (206). Given that Wnt signaling and WISP1 are also involved in metabolic pathways (60, 244, 258–261), EPO also provides cellular protection during metabolic disorders through Wnt signaling (262–265). …”

Section: Erythropoietin and The Modulation Of Mtormentioning

confidence: 99%

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Maiese¹

2016

CNR

View full text Add to dashboard Cite

Life expectancy continues to increase throughout the world, but is accompanied by a rise in the incidence of non-communicable diseases. As a result, the benefits of an increased lifespan can be limited by aging-related disorders that necessitate new directives for the development of effective and safe treatment modalities. With this objective, the mechanistic target of rapamycin (mTOR), a 289-kDa serine/threonine protein, and its related pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), proline rich Akt substrate 40 kDa (PRAS40), AMP activated protein kinase (AMPK), Wnt signaling, and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), have generated significant excitement for furthering novel therapies applicable to multiple systems of the body. Yet, the biological and clinical outcome of these pathways can be complex especially with oversight of cell death mechanisms that involve apoptosis and autophagy. Growth factors, and in particular erythropoietin (EPO), are one avenue under consideration to implement control over cell death pathways since EPO can offer potential treatment for multiple disease entities and is intimately dependent upon mTOR signaling. In experimental and clinical studies, EPO appears to have significant efficacy in treating several disorders including those involving the developing brain. However, in mature populations that are affected by aging-related disorders, the direction for the use of EPO to treat clinical disease is less clear that may be dependent upon a number of factors including the understanding of mTOR signaling. Continued focus upon the regulatory elements that control EPO and mTOR signaling could generate critical insights for targeting a broad range of clinical maladies.

show abstract

“…WISP1 expression is altered by weight change in humans and increases during insulin resistance in glucosetolerant individuals (Murahovschi et al 2015), suggestive that WISP1 may represent an important reparative process in individuals with DM. However, WISP1 expression has recently been linked to gestational diabetes with additional studies required to determine its role in this disorder (Sahin Ersoy et al 2016).…”

Section: Wisp1 In Cellular Repair and Proliferationmentioning

confidence: 99%

WISP1i

2018

Encyclopedia of Signaling Molecules

View full text Add to dashboard Cite

WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus

Cited by 39 publications

References 32 publications

Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women

Association of WISP1/CCN4 with Risk of Overweight and Gestational Diabetes Mellitus in Chinese Pregnant Women

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

WISP1i

Contact Info

Product

Resources

About